Antinuclear Antibody Test Market: Current Analysis and Forecast (2021-2027)

The Global Antinuclear Antibody Test Market is anticipated to grow with an elevated CAGR of around 12% over the forecast period (2021-2027). Antibodies are proteins that the immune system forms to fight bacteria, viruses, and pathogens. sometimes, the immune system can mistake parts of its own body for foreign bodies. It releases special antibodies, known as autoantibodies that attack its own body cells and tissues.

The rising prevalence of chronic diseases and increasing autoimmune disorders are the main factors that are responsible for the rising demand for antinuclear antibody tests. Furthermore, rising awareness among the population about the severity of the diseases and the increasing efforts in R&D also have significant contributions to the growth of the antinuclear antibody test market. For instance, as per MedlinePlus, Sjogren syndrome is a relatively common disorder; it occurs in 0.1 to 1 percent of the population. It is difficult to determine the exact prevalence because the characteristic features of this disorder, dry eyes, and dry mouth, can also be caused by many other conditions.

Zeus Scientific Inc., Antibodies Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, ERBA Diagnostics Inc., EUROIMMUN AG, Trinity Biotech plc, Alere Inc., Inova Diagnostics, Immuno Concepts are some of the prominent players operating in the antinuclear antibody test market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with new varieties of the antinuclear antibody test.

The global impact of COVID-19 has been unprecedented and staggering, with the market registering a certain decline across all regions amid the pandemic. The antinuclear antibody test market was also affected by the crisis due to the unavailability of treatment in hospitals. Additionally, many people postponed their inessential appointments, as well as the healthcare systems, were engaged in severe diseases and managing the COVID-19 cases even specialty clinics were also engaged in COVID-19 treatments during the pandemic therefore the decline in demand for antinuclear antibody tests was observed.

Insights Presented in the Report:

Amongst Products, Reagents & Assay kits segment holds the major share"

Based on products, the market is categorized into reagents & assay kits, systems, software & services. The reagents & assay kits segment grabbed a significant market share in 2020 and is anticipated to grow at a rapid rate in the upcoming years. This is mainly due to the reagents & assay kits providing accurate, and rapid results, and accurate solutions. Furthermore, the rising number of research laboratories and increasing use of the reagents in them is attributed to the segmental growth of reagents & assay kits in the antinuclear antibody test market.

"Amongst Technique, ELISA segment holds the major share"

Based on the technique, the market is categorized into ELISA, immunofluorescence assay, and multiplex assay. The ELISA segment accounted for a significant market share in 2020 and it is estimated that it will exhibit a higher CAGR during the forecast period. This is mainly due to the technique providing higher sensitivity and specificity in the test. The higher sensitivity is due to the involvement of the enzyme in the process resulting in the amplification of the process. Furthermore, the binding of antigen or antibody only occurs at specific sites of an antigen or antigen-binding site of an antibody ensuring the specificity of the test.

Amongst Application, the Rheumatoid Arthritis segment holds the major share"

Based on application, the market is divided into the market is categorized into rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, and others. The rheumatoid arthritis segment grabbed a significant market share in 2020. The rising prevalence of arthritis is the important factor that is catalyzing the market growth of the segment during the forecast year. For instance, as per the CDC, from 2013-2015, an estimated 58.5 million US adults annually. It is projected to reach 78 million (26%) US adults by 2040.

Amongst End-users, the Hospitals & Clinics segment holds the major share"

Based on the end-users, the market is categorized into hospitals & clinics, diagnostic centers, and others. The hospitals & clinics segment accounted for a significant market share in 2020 and it is estimated that it will exhibit a higher CAGR during the forecast period. The presence of specialized professionals and appropriate infrastructure for the disease treatment under a single roof attributed to the growth of the segment in the antinuclear antibody market. Furthermore, the rising investment in hospitals is also being a contributing factor to the market growth of the antinuclear antibody test. For instance, as per NITI Aayog, the long-term outlook for the hospital sector is stable, with annual revenues likely to grow over the next few years on account of rising domestic demand for healthcare and medical tourism. It was valued at USD 61.79 Billion in 2017 and is expected to reach USD 132 Billion by 2023.

"North America represents one of the largest markets of antinuclear antibody test market"

For a better understanding of the market dynamics of the antinuclear antibody test market, a detailed analysis was conducted for different regions across the globe including North America (U.S, Canada, and the Rest of North America), Europe (Germany, France, Spain, United Kingdom, Italy, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. In 2020, North America has a significant share of the antinuclear antibody test industry. This can be mainly due to the presence of well-established market players and the higher disposable income of the people in the region is responsible for the market growth of the diagnostic industry including the antinuclear antibody test market. For instance, according to the Bureau Of Economic Analysis Personal income increased $113.4 billion (0.5 percent) in May 2022. Disposable personal income (DPI) increased $96.5 billion (0.5 percent) and personal consumption expenditures (PCE) increased $32.7 billion (0.2 percent).

Reasons to buy this report:

The study includes market sizing and forecasting analysis validated by authenticated key industry experts

The report presents a quick review of overall industry performance at one glance

The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments

Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry

The study comprehensively covers the market across different segments

Deep dive regional level analysis of the industry

Customization Options:

The global antinuclear antibody test market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.